Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased due to expanding demand for biosimilar drug substances and other products, higher deliveries and revisions to supply prices. Profit declined due to higher research and development expenses, increased manufacturing costs resulting from yen depreciation, fees paid, losses on disposal of inventories, losses on cancellation of lease agreements and other items.
Material events, etc. have been disclosed. The company determined that the existence of a consolidated operating loss ahead of schedule created circumstances giving rise to significant doubt regarding the going concern assumption, but concluded that no material uncertainty existed. There were no matters to disclose in the notes on the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥6,589 million (YoY +29.7%) |
| Operating profit | ¥-138 million |
| Ordinary income | ¥-374 million |
| Profit attributable to owners of the parent | ¥-413 million |
| Net income per share | -¥8.48 |
| Operating Margin | -2.1 |
| Equity ratio | End of the current fiscal period 26.4 / End of previous period 19.1 |
| Total assets | ¥6,088 million |
| Net assets | ¥1,653 million |
| Cash flows from operating activities | ¥-1,096 million |
| Cash flows from investing activities | ¥-12 million |
| Cash flows from financing activities | ¥1,397 million |
| Cash and cash equivalents at end of period | ¥3,294 million |
| Full-year earnings forecast | Net Sales 5,000～6,000 / Operating profit 100～600 / Ordinary income Not disclosed / Net income Not disclosed |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥245 thousand |
| Impairment loss | ¥0 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on reversal of subscription rights to shares / Amount ¥10,608 thousand / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥1,049 thousand, Item Impairment loss on investment securities / Amount ¥15,797 thousand, Item Loss on cancellation of lease agreements / Amount ¥21,774 thousand |
| Disclosure regarding the going concern assumption | Material events, etc. have been disclosed. The company determined that the existence of a consolidated operating loss ahead of schedule created circumstances giving rise to significant doubt regarding the going concern assumption, but concluded that no material uncertainty existed. There were no matters to disclose in the notes on the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 49,623,419 |
| Treasury Shares at Period-End | 94 |
| Factors Behind Changes in Business Performance | Revenue increased due to expanding demand for biosimilar drug substances and other products, higher deliveries and revisions to supply prices. Profit declined due to higher research and development expenses, increased manufacturing costs resulting from yen depreciation, fees paid, losses on disposal of inventories, losses on cancellation of lease agreements and other items. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as deliveries progressed amid continued demand for biosimilar drug substances and other products, and as the impact of revised supply prices contributed throughout the fiscal year. The main factor behind the operating loss was an increase in research and development expenses related to measures to reduce manufacturing costs, the development of new biosimilars and preparations for clinical trials in the cell therapy business. The ordinary loss reflected the recognition of fees paid in connection with the arrangement of syndicated loans, losses on disposal of inventories and other items. The net loss was attributed to extraordinary losses, including losses on cancellation of lease agreements.